A follow-up study of urinary markers of aflatoxin exposure and liver cancer risk in Shanghai, People's Republic of China - PubMed (original) (raw)
. 1994 Jan-Feb;3(1):3-10.
Affiliations
- PMID: 8118382
A follow-up study of urinary markers of aflatoxin exposure and liver cancer risk in Shanghai, People's Republic of China
G S Qian et al. Cancer Epidemiol Biomarkers Prev. 1994 Jan-Feb.
Abstract
A cohort of 18,244 mostly middle-aged (45-64 years) men residing in four small geographically defined areas of Shanghai was accrued between January 1986 and September 1989. In addition to an in-person interview regarding dietary and other past exposures, each subject donated a single void urine sample at recruitment so that the presence of aflatoxins in urine could be assessed. In addition, a 1-year survey of market foods in Shanghai was conducted to quantitatively estimate the extent of aflatoxin exposure in the study population. After close to 70,000 person-years of follow-up, 55 incident cases of hepatocellular carcinoma (HCC) had been identified. Levels of urinary aflatoxin B1 and the oxidative metabolites, including the major aflatoxin nucleic acid adduct, aflatoxin-N7-guanine, were determined for 50 of the 55 identified cases of HCC. Two hundred sixty-seven controls were chosen randomly from the cohort; they were matched to the 50 cases by age (within 1 year), time of specimen collection (within 1 month), and residence. After integrating the high-pressure liquid chromatography chromatograms to measure aflatoxin-N7-guanine, aflatoxin M1, aflatoxin P1, and aflatoxin B1, 49, 67, 53, and 71 of the urine samples had detectable levels of these compounds, respectively. The aflatoxin metabolite detected at the highest concentration was aflatoxin P1; the range was 0.59-16.0 ng/ml. The range of aflatoxin M1 in the urine was 0.17-5.2 ng/ml. The aflatoxin-N7-guanine adduct range was 0.3-1.81 ng/ml in the 49 positive samples.(ABSTRACT TRUNCATED AT 250 WORDS)
Comment in
- Correspondence re: G-S. Qian, et al., A follow-up study of urinary markers of aflatoxin exposure and liver cancer risk in Shanghai, People's Republic of China. Cancer Epidemiol., Biomarkers & Prev., 3:3-10, 1994, and C.C. Harris, Solving the viral-chemical puzzle of human liver carcinogenesis. Cancer Epidemiol., Biomarkers & Prev., 3:1-2, 1994.
Campbell TC. Campbell TC. Cancer Epidemiol Biomarkers Prev. 1994 Sep;3(6):519-21. Cancer Epidemiol Biomarkers Prev. 1994. PMID: 8000305 No abstract available. - Solving the viral-chemical puzzle of human liver carcinogenesis.
Harris CC. Harris CC. Cancer Epidemiol Biomarkers Prev. 1994 Jan-Feb;3(1):1-2. Cancer Epidemiol Biomarkers Prev. 1994. PMID: 8118377 No abstract available.
Similar articles
- Molecular dosimetry of urinary aflatoxin-DNA adducts in people living in Guangxi Autonomous Region, People's Republic of China.
Groopman JD, Zhu JQ, Donahue PR, Pikul A, Zhang LS, Chen JS, Wogan GN. Groopman JD, et al. Cancer Res. 1992 Jan 1;52(1):45-52. Cancer Res. 1992. PMID: 1727385 - Molecular dosimetry of aflatoxin-N7-guanine in human urine obtained in The Gambia, West Africa.
Groopman JD, Hall AJ, Whittle H, Hudson GJ, Wogan GN, Montesano R, Wild CP. Groopman JD, et al. Cancer Epidemiol Biomarkers Prev. 1992 Mar-Apr;1(3):221-7. Cancer Epidemiol Biomarkers Prev. 1992. PMID: 1339082 - Urinary aflatoxin biomarkers and risk of hepatocellular carcinoma.
Ross RK, Yuan JM, Yu MC, Wogan GN, Qian GS, Tu JT, Groopman JD, Gao YT, Henderson BE. Ross RK, et al. Lancet. 1992 Apr 18;339(8799):943-6. doi: 10.1016/0140-6736(92)91528-g. Lancet. 1992. PMID: 1348796 - Changing pattern of hepatocellular carcinoma (HCC) and its risk factors in Egypt: possibilities for prevention.
Anwar WA, Khaled HM, Amra HA, El-Nezami H, Loffredo CA. Anwar WA, et al. Mutat Res. 2008 Jul-Aug;659(1-2):176-84. doi: 10.1016/j.mrrev.2008.01.005. Epub 2008 Jan 20. Mutat Res. 2008. PMID: 18346933 Review. - The use of monoclonal antibody affinity columns for assessing DNA damage and repair following exposure to aflatoxin B1.
Groopman JD, Kensler TW. Groopman JD, et al. Pharmacol Ther. 1987;34(2):321-34. doi: 10.1016/0163-7258(87)90016-7. Pharmacol Ther. 1987. PMID: 3120202 Review.
Cited by
- Global epidemiology of hepatocellular carcinoma: an emphasis on demographic and regional variability.
McGlynn KA, Petrick JL, London WT. McGlynn KA, et al. Clin Liver Dis. 2015 May;19(2):223-38. doi: 10.1016/j.cld.2015.01.001. Epub 2015 Feb 26. Clin Liver Dis. 2015. PMID: 25921660 Free PMC article. Review. - Comprehensive Metabolomic Analysis Reveals Dynamic Metabolic Reprogramming in Hep3B Cells with Aflatoxin B1 Exposure.
Wang S, Yang X, Liu F, Wang X, Zhang X, He K, Wang H. Wang S, et al. Toxins (Basel). 2021 May 27;13(6):384. doi: 10.3390/toxins13060384. Toxins (Basel). 2021. PMID: 34072178 Free PMC article. - Aflatoxin: a 50-year odyssey of mechanistic and translational toxicology.
Kensler TW, Roebuck BD, Wogan GN, Groopman JD. Kensler TW, et al. Toxicol Sci. 2011 Mar;120 Suppl 1(Suppl 1):S28-48. doi: 10.1093/toxsci/kfq283. Epub 2010 Sep 29. Toxicol Sci. 2011. PMID: 20881231 Free PMC article. Review. - Chlorophyllin intervention reduces aflatoxin-DNA adducts in individuals at high risk for liver cancer.
Egner PA, Wang JB, Zhu YR, Zhang BC, Wu Y, Zhang QN, Qian GS, Kuang SY, Gange SJ, Jacobson LP, Helzlsouer KJ, Bailey GS, Groopman JD, Kensler TW. Egner PA, et al. Proc Natl Acad Sci U S A. 2001 Dec 4;98(25):14601-6. doi: 10.1073/pnas.251536898. Epub 2001 Nov 27. Proc Natl Acad Sci U S A. 2001. PMID: 11724948 Free PMC article. Clinical Trial. - Hepatocellular carcinoma and the underlying mechanisms.
Oyagbemi AA, Azeez OI, Saba AB. Oyagbemi AA, et al. Afr Health Sci. 2010 Mar;10(1):93-8. Afr Health Sci. 2010. PMID: 20811532 Free PMC article.
Publication types
MeSH terms
Substances
Grants and funding
- R01 CA043092/CA/NCI NIH HHS/United States
- CA48409/CA/NCI NIH HHS/United States
- R01 CA043092-20/CA/NCI NIH HHS/United States
- CA47128/CA/NCI NIH HHS/United States
- CA43092/CA/NCI NIH HHS/United States
LinkOut - more resources
Medical
Miscellaneous